Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for ARNA
+1.79 (4.99%)
After Hours: 37.68 0.00 (0.00%)
Jan 23, 4:36PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.81 - 37.80
52 week 11.30 - 41.92
Open 35.90
Vol / Avg. 610,912.00/604,630.00
Mkt cap 1.48B
P/E     -
Div/yield     -
EPS -0.94
Shares 39.26M
Beta 1.49
Inst. own 74%
Mar 12, 2018
Q4 2017 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jan 29, 2018
Arena Pharmaceuticals Inc Hosts a Key Opinion Leader Event on Sphingosine-1-Phosphate Receptor Modulation in the treatment of Autoimmune Diseases - Analyst Meeting - 12:00PM EST - Add to calendar
Jan 10, 2018
Arena Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Nov 8, 2017
Arena Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Webcast
Nov 7, 2017
Q3 2017 Arena Pharmaceuticals Inc Earnings Call - Webcast
Nov 7, 2017
Q3 2017 Arena Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -410.97% -18.47%
Operating margin -403.70% -13.83%
EBITD margin - 15.56%
Return on average assets -48.78% -10.75%
Return on average equity -86.10% -48.19%
Employees 106 -
CDP Score - -


6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Officers and directors

Tina Susan Nova Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Amit D. Munshi President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Kevin R. Lind Chief Financial Officer, Executive Vice President
Age: 41
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
Vincent Aurentz Executive Vice President and Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Executive Vice President - Research & Development, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Jennifer Jarrett Director
Age: 46
Bio & Compensation  - Reuters
Scott H. Bice J.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Jayson Dallas M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Oliver S. Fetzer Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters